COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
July 28, 2022 04:00 ET | COMPASS Pathways
Multi-centre, double-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which there is currently no approved pharmacological...
COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression
May 03, 2022 07:00 ET | COMPASS Pathways
Positive early signals seen in two investigator-initiated studies presented at the Society of Biological Psychiatry Annual Meeting in New Orleans London, UK – 3 May 2022        COMPASS...
Monte Nido & Affiliates Brings Two Residential Eating Disorder Programs to Chicagoland
February 20, 2020 15:50 ET | Monte Nido & Affiliates
CHICAGO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Monte Nido & Affiliates, the nation’s leading provider of eating disorder treatment for over 24 years, announces the opening of two residential eating...
Changing the Way the World Thinks About Eating Disorders - A Free Webinar from the Brain & Behavior Research Foundation
November 21, 2019 09:00 ET | Brain & Behavior Research Foundation
New York, Nov. 21, 2019 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation is hosting a free webinar “Changing the Way the World Thinks About Eating Disorders” on Tuesday, December 10,...